Aberrant epigenetic silencing of neuronatin is a frequent event in human osteosarcoma.

Title

Aberrant epigenetic silencing of neuronatin is a frequent event in human osteosarcoma.

Creator

Saeed H; Sinha S; Mella C; Kuerbitz JS; Cales ML; Steele MA; Stanke J; Damron D; Safadi F; Kuerbitz SJ

Publisher

Oncotarget

Date

2020
2020-05

Description

The paternally imprinted neuronatin (NNAT) gene has been identified as a target of aberrant epigenetic silencing in diverse cancers, but no association with pediatric bone cancers has been reported to date. In screening childhood cancers, we identified aberrant CpG island hypermethylation in a majority of osteosarcoma (OS) samples and in 5 of 6 human OS cell lines studied but not in normal bone-derived tissue samples. CpG island hypermethylation was associated with transcriptional silencing in human OS cells, and silencing was reversible upon treatment with

Subject

DNA methylation; neuronatin; osteosarcoma; tumor suppressor genes

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Format

journalArticle

Search for Full-text

Users with a NEOMED Library login can search for full-text journal articles at the following url: https://libraryguides.neomed.edu/home

Pages

1876–1893

Issue

20

Volume

11

NEOMED College

NEOMED College of Medicine
NEOMED College of Pharmacy

NEOMED Department

Department of Anatomy & Neurobiology
Department of Pharmaceutical Sciences
Department of Pediatrics

Update Year & Number

July 2020 List

Affiliated Hospital

Akron Children's Hospital

Citation

Saeed H; Sinha S; Mella C; Kuerbitz JS; Cales ML; Steele MA; Stanke J; Damron D; Safadi F; Kuerbitz SJ, “Aberrant epigenetic silencing of neuronatin is a frequent event in human osteosarcoma.,” NEOMED Bibliography Database, accessed January 24, 2021, https://neomed.omeka.net/items/show/11161.

Social Bookmarking